India · Delayed Price · Currency is INR Jagsonpal Pharmaceuticals Statistics
Total Valuation
NSE:JAGSNPHARM has a market cap or net worth of INR 14.33 billion. The enterprise value is 13.30 billion.
| Market Cap | 14.33B |
| Enterprise Value | 13.30B |
Important Dates
The last earnings date was Thursday, October 29, 2026.
| Earnings Date | Oct 29, 2026 |
| Ex-Dividend Date | Sep 4, 2026 |
Share Statistics
NSE:JAGSNPHARM has 66.06 million shares outstanding. The number of shares has increased by 0.46% in one year.
| Current Share Class | 66.06M |
| Shares Outstanding | 66.06M |
| Shares Change (YoY) | +0.46% |
| Shares Change (QoQ) | +0.81% |
| Owned by Insiders (%) | 12.21% |
| Owned by Institutions (%) | 2.38% |
| Float | 15.02M |
Valuation Ratios
The trailing PE ratio is 32.54.
| PE Ratio | 32.54 |
| Forward PE | n/a |
| PS Ratio | 4.54 |
| PB Ratio | 5.87 |
| P/TBV Ratio | 10.02 |
| P/FCF Ratio | 30.18 |
| P/OCF Ratio | 30.10 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 21.61, with an EV/FCF ratio of 28.02.
| EV / Earnings | 29.44 |
| EV / Sales | 4.21 |
| EV / EBITDA | 21.61 |
| EV / EBIT | 25.33 |
| EV / FCF | 28.02 |
Financial Position
The company has a current ratio of 3.42, with a Debt / Equity ratio of 0.04.
| Current Ratio | 3.42 |
| Quick Ratio | 2.82 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | 0.15 |
| Debt / FCF | 0.19 |
| Interest Coverage | 61.21 |
Financial Efficiency
Return on equity (ROE) is 18.18% and return on invested capital (ROIC) is 24.84%.
| Return on Equity (ROE) | 18.18% |
| Return on Assets (ROA) | 10.63% |
| Return on Invested Capital (ROIC) | 24.84% |
| Return on Capital Employed (ROCE) | 19.89% |
| Weighted Average Cost of Capital (WACC) | 2.85% |
| Revenue Per Employee | 2.43M |
| Profits Per Employee | 348,419 |
| Employee Count | 1,297 |
| Asset Turnover | 1.02 |
| Inventory Turnover | 5.70 |
Taxes
In the past 12 months, NSE:JAGSNPHARM has paid 151.87 million in taxes.
| Income Tax | 151.87M |
| Effective Tax Rate | 25.15% |
Stock Price Statistics
The stock price has increased by +2.62% in the last 52 weeks. The beta is -0.26, so NSE:JAGSNPHARM's price volatility has been lower than the market average.
| Beta (5Y) | -0.26 |
| 52-Week Price Change | +2.62% |
| 50-Day Moving Average | 227.05 |
| 200-Day Moving Average | 209.71 |
| Relative Strength Index (RSI) | 44.72 |
| Average Volume (20 Days) | 67,612 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, NSE:JAGSNPHARM had revenue of INR 3.16 billion and earned 451.90 million in profits. Earnings per share was 6.67.
| Revenue | 3.16B |
| Gross Profit | 1.95B |
| Operating Income | 525.17M |
| Pretax Income | 603.76M |
| Net Income | 451.90M |
| EBITDA | 599.69M |
| EBIT | 525.17M |
| Earnings Per Share (EPS) | 6.67 |
Balance Sheet
The company has 1.15 billion in cash and 92.16 million in debt, with a net cash position of 1.06 billion or 16.05 per share.
| Cash & Cash Equivalents | 1.15B |
| Total Debt | 92.16M |
| Net Cash | 1.06B |
| Net Cash Per Share | 16.05 |
| Equity (Book Value) | 2.44B |
| Book Value Per Share | 36.42 |
| Working Capital | 1.31B |
Cash Flow
In the last 12 months, operating cash flow was 476.02 million and capital expenditures -1.27 million, giving a free cash flow of 474.75 million.
| Operating Cash Flow | 476.02M |
| Capital Expenditures | -1.27M |
| Depreciation & Amortization | 74.52M |
| Net Borrowing | -6.11M |
| Free Cash Flow | 474.75M |
| FCF Per Share | 7.19 |
Margins
Gross margin is 61.68%, with operating and profit margins of 16.63% and 14.31%.
| Gross Margin | 61.68% |
| Operating Margin | 16.63% |
| Pretax Margin | 19.12% |
| Profit Margin | 14.31% |
| EBITDA Margin | 18.99% |
| EBIT Margin | 16.63% |
| FCF Margin | 15.04% |
Dividends & Yields
This stock pays an annual dividend of 2.50, which amounts to a dividend yield of 1.15%.
| Dividend Per Share | 2.50 |
| Dividend Yield | 1.15% |
| Dividend Growth (YoY) | 60.00% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 58.38% |
| FCF Payout Ratio | 55.66% |
| Buyback Yield | -0.46% |
| Shareholder Yield | 0.70% |
| Earnings Yield | 3.07% |
| FCF Yield | 3.31% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |
| Graham Formula Value | |
| Graham Formula Upside |
Stock Splits
The last stock split was on January 8, 2025. It was a forward split with a ratio of 2.5.
| Last Split Date | Jan 8, 2025 |
| Split Type | Forward |
| Split Ratio | 2.5 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 5 |